265 related articles for article (PubMed ID: 15542506)
1. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
[TBL] [Abstract][Full Text] [Related]
2. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
[TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
[TBL] [Abstract][Full Text] [Related]
4. A cost-utility analysis of ablative therapy for Barrett's esophagus.
Inadomi JM; Somsouk M; Madanick RD; Thomas JP; Shaheen NJ
Gastroenterology; 2009 Jun; 136(7):2101-2114.e1-6. PubMed ID: 19272389
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.
Hur C; Nishioka NS; Gazelle GS
Dig Dis Sci; 2003 Jul; 48(7):1273-83. PubMed ID: 12870783
[TBL] [Abstract][Full Text] [Related]
9. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D; Schmitt C; Wong JB
Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
[TBL] [Abstract][Full Text] [Related]
10. A guide for surveillance of patients with Barrett's esophagus.
Provenzale D; Kemp JA; Arora S; Wong JB
Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
[TBL] [Abstract][Full Text] [Related]
11. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus.
Boger PC; Turner D; Roderick P; Patel P
Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1332-42. PubMed ID: 21050235
[TBL] [Abstract][Full Text] [Related]
12. An analysis of esophagectomy and other techniques in the management of high-grade dysplasia of Barrett's esophagus.
Deb SJ; Shen KR; Deschamps C
Dis Esophagus; 2012 May; 25(4):356-66. PubMed ID: 21518102
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients with various Barrett's esophagus associated health states.
Hur C; Wittenberg E; Nishioka NS; Gazelle GS
Health Qual Life Outcomes; 2006 Aug; 4():45. PubMed ID: 16884539
[TBL] [Abstract][Full Text] [Related]
14. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.
Comay D; Blackhouse G; Goeree R; Armstrong D; Marshall JK
Can J Gastroenterol; 2007 Apr; 21(4):217-22. PubMed ID: 17431509
[TBL] [Abstract][Full Text] [Related]
16. Barrett's oesophagus: a review of costs of the illness.
Arguedas MR; Eloubeidi MA
Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
[TBL] [Abstract][Full Text] [Related]
17. Invasive carcinoma after endoscopic ablative therapy for high-grade dysplasia in Barrett's oesophagus.
van Hillegersberg R; Haringsma J; ten Kate FJ; Tytgat GN; van Lanschot JJ
Dig Surg; 2003; 20(5):440-4. PubMed ID: 12900536
[TBL] [Abstract][Full Text] [Related]
18. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus.
Sujendran V; Sica G; Warren B; Maynard N
Eur J Cardiothorac Surg; 2005 Nov; 28(5):763-6. PubMed ID: 16188449
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
Gerson LB; Groeneveld PW; Triadafilopoulos G
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
[TBL] [Abstract][Full Text] [Related]
20. Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.
Gordon LG; Hirst NG; Mayne GC; Watson DI; Bright T; Cai W; Barbour AP; Smithers BM; Whiteman DC; Eckermann S;
J Gastrointest Surg; 2012 Aug; 16(8):1451-61. PubMed ID: 22644445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
